Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Licheng Zhou

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|November 11, 2022
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL InhibitorsShingpan Chan, Yunong Zhang, Jie Wang, et al.
Journal of Medicinal Chemistry|October 10, 2024
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC DegraderLicheng Zhou, Kaijie Zhou, Yu Chang, et al.
Journal of Medicinal Chemistry|March 13, 2025
Discovery of <b>YJZ5118</b>: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt InhibitionJianzhang Yang, Yu Chang, Kaijie Zhou, et al.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
The Journal of Clinical Investigation|September 16, 2025
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsYi Bao, Yu Chang, Jean Ching-Yi Tien, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|November 11, 2022
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL InhibitorsShingpan Chan, Yunong Zhang, Jie Wang, et al.
Journal of Medicinal Chemistry|October 10, 2024
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC DegraderLicheng Zhou, Kaijie Zhou, Yu Chang, et al.
Journal of Medicinal Chemistry|March 13, 2025
Discovery of <b>YJZ5118</b>: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt InhibitionJianzhang Yang, Yu Chang, Kaijie Zhou, et al.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
The Journal of Clinical Investigation|September 16, 2025
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsYi Bao, Yu Chang, Jean Ching-Yi Tien, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Pageof 5